TOT BIOPHARM International Company Limited
HKEX:1875.HK
2 (HKD) • At close September 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 351.6 | 417.769 | 152.805 | 225.533 | 539.18 | 256.751 | 24.581 |
| Short Term Investments
| 6.764 | 40.278 | 2.577 | 2.598 | 32.139 | 17.332 | 47.835 |
| Cash and Short Term Investments
| 351.6 | 458.047 | 152.805 | 225.533 | 571.319 | 274.083 | 72.416 |
| Net Receivables
| 140.705 | 58.402 | 23.687 | 2.438 | 9.191 | 8.998 | 8.312 |
| Inventory
| 126.009 | 94.821 | 29.558 | 8.114 | 15.25 | 3.105 | 0.98 |
| Other Current Assets
| 0.017 | 38.254 | 79.862 | 5.316 | 43.308 | 22.499 | 14.578 |
| Total Current Assets
| 693.175 | 676.797 | 305.963 | 249.227 | 614.363 | 299.687 | 87.974 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 699.229 | 562.812 | 365.832 | 297.748 | 323.889 | 316.42 | 226.165 |
| Goodwill
| 0 | -12.982 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 21.475 | 17.63 | 18.451 | 16.903 | 16.411 | 16.267 | 15.441 |
| Goodwill and Intangible Assets
| 21.475 | 4.648 | 18.451 | 16.903 | 16.411 | 16.267 | 15.441 |
| Long Term Investments
| 0 | -37.097 | 1.483 | 8.076 | -24.148 | -10.522 | -41.38 |
| Tax Assets
| 0 | 40.281 | 18.363 | 69.127 | 86.671 | 55.19 | 75.443 |
| Other Non-Current Assets
| 12.222 | 14.59 | 0.171 | 0.102 | 0.176 | 0.196 | 0.414 |
| Total Non-Current Assets
| 732.926 | 585.234 | 404.3 | 391.956 | 402.999 | 377.551 | 276.083 |
| Total Assets
| 1,426.101 | 1,262.031 | 710.263 | 641.183 | 1,017.362 | 677.238 | 364.057 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 35.71 | 25.983 | 28.214 | 18.006 | 0 | 0 | 0 |
| Short Term Debt
| 42.772 | 77.051 | 147.654 | 1.323 | 62.775 | 2.817 | 3.833 |
| Tax Payables
| 1.659 | 2.537 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 299.287 | 167.596 | 80.223 | -1.323 | 0 | 0 | 0 |
| Other Current Liabilities
| 4.717 | 4.717 | 4.717 | 34.737 | 84.011 | 72.322 | 17.954 |
| Total Current Liabilities
| 382.486 | 275.347 | 260.808 | 52.743 | 146.786 | 75.139 | 21.787 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 302.879 | 212.478 | 60.911 | 6.083 | 12.299 | 12.81 | 264.954 |
| Deferred Revenue Non-Current
| 11 | 11 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | -11 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 43.05 | 58.767 | 53.453 | 0 | 0 | 773.767 | 0 |
| Total Non-Current Liabilities
| 356.929 | 271.245 | 114.364 | 6.083 | 12.299 | 786.577 | 264.954 |
| Total Liabilities
| 739.415 | 546.592 | 375.172 | 58.826 | 159.085 | 861.716 | 286.741 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock
| 2,297.499 | 2,297.499 | 1,892.906 | 1,874.438 | 1,874.438 | 537.859 | 537.859 |
| Retained Earnings
| -1,683.285 | -1,645.528 | -1,595.612 | -1,341.584 | -1,053.086 | -753.786 | -485.523 |
| Accumulated Other Comprehensive Income/Loss
| 72.472 | 61.911 | 37.797 | 49.503 | 36.925 | -67.216 | -54.005 |
| Other Total Stockholders Equity
| 0 | 0 | 0 | 0 | 0 | 98.665 | 78.985 |
| Total Shareholders Equity
| 686.686 | 713.882 | 335.091 | 582.357 | 858.277 | -184.478 | 77.316 |
| Total Equity
| 686.686 | 715.439 | 335.091 | 582.357 | 858.277 | -184.478 | 77.316 |
| Total Liabilities & Shareholders Equity
| 1,426.101 | 1,262.031 | 710.263 | 641.183 | 1,017.362 | 677.238 | 364.057 |